SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

Communiqués Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Deutsche Boerse AG

Actions

08HH

CNE100001M79

Produits pharmaceutiques

Marché Fermé - Deutsche Boerse AG 08:01:32 16/09/2026			Varia. 5j.	Varia. 1 janv.
1,871 ^EUR	+1,00%		-0,90%	-10,73%

14/09	Le régulateur chinois du médicament accepte la demande de Fosun Pharma pour le HLX14 ; l'action grimpe de 5%	MT
08/09	Fosun Pharma obtient l'approbation en Chine pour un essai de phase 2/3 sur un traitement du vitiligo	MT

Communiqués

06/09	Shanghai Fosun Pharmaceutical : Fosun Pharma Announces H-Share Repurchase Plan of Up to HK$ 1 Billion	PU
19/08/25	Fosun Pharma's Self-Developed Innovative Drug Luvometinib Tablets Gains Breakthrough Therapy Designation in Saudi Arabia	AQ
17/07/25	Shanghai Fosun Pharmaceutical : Fosun Pharma’s Self-Developed New Drug XH-S004 for the Treatment of Chronic Obstructive Pulmonary Disease Enters Phase 1b Clinical Trial	PU
10/07/25	Shanghai Fosun Pharmaceutical : Fosun Pharma's Self-developed Innovative Drug Luvometinib Tablets for the Treatment of Pediatric Low-grade Glioma Indication Enters Phase 3 Clinical Trial in China	PU
24/06/25	Shanghai Fosun Pharmaceutical : Fosun Pharma Completes Board Election, Accelerating Innovation Transformation and Global Development	PU
17/06/25	Fosun Pharma and Teva have reached a strategic cooperation to jointly develop a new anti-PD1-IL2 therapy for tumor immunotherapy	AQ
06/02/25	Shanghai Fosun Pharmaceutical : Fosun Pharma’s Self developed anti PD 1 mAb Serplulimab Approved in the EU for First Line Treatment of Extensive Stage Small Cell Lung Cancer (ES SCLC)	PU
12/12/23	Shanghai Fosun Pharmaceutical : Fosun Pharma and Insightec Establish Joint Venture to Expand Global Access to Focused Ultrasound Treatment for Neurological Diseases	PU
30/03/23	Fosun Pharma’s 15th Corporate Social Responsibility Report: Continuous Innovation for the Benefit of the Public	PU
20/01/23	Shanghai Fosun Pharmaceutical : COMIRNATY® Bivalent COVID-19 Vaccine is Officially Approved as Regular Imported Vaccine by the Pharmaceutical Administration Bureau of Macao SAR	PU
06/01/23	Shanghai Fosun Pharmaceutical : Self-Paid Vaccination Service for Bivalent COVID-19 Vaccine COMIRNATY® is Officially Provided in Hong Kong, Offering More Vaccine Options for People in Need	PU
30/10/22	Shanghai Fosun Pharmaceutical : Fosun Pharma Announces Results for the First Three Quarters of 2022	PU
13/10/22	Shanghai Fosun Pharmaceutical : Fosun Pharma’s MSCI ESG Rating Upgraded to A	PU
08/09/22	Neovii and Fosun Pharma Enter into an Exclusive Agreement	AQ
25/08/22	Shanghai Fosun Pharmaceutical : Fosun Pharma Topped the 2022 Fortune China ESG Impact List	PU
27/06/22	Shanghai Fosun Pharmaceutical : Fosun Pharma and Amgen Announce Collaboration to Accelerate Two Innovative Medicines Benefitting Chinese Patients	PU
17/06/22	Shanghai Fosun Pharmaceutical : Continuously Promoting Innovation and Internationalization Fosun Pharma Presents at 2022 BIO International Convention	PU
06/06/22	Shanghai Fosun Pharmaceutical : VOLUNTARY ANNOUNCEMENT - ENTERING INTO SALE AND PURCHASE AGREEMENTS （H SHARES）	PU
02/06/22	Shanghai Fosun Pharmaceutical : MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MAY 2022(H SHARES)	PU
01/06/22	Shanghai Fosun Pharmaceutical : (1) RE-APPOINTMENT OF CHAIRMAN AND VICE CHAIRMAN (2) APPOINTMENT OF CO-CHAIRMAN (3) APPOINTMENT OF CHIEF EXECUTIVE OFFICER AND CO-CHIEF EXECUTIVE OFFICER AND (4) CHANGE IN BOARD COMMITTEE COMPOSITION	PU
25/05/22	Shanghai Fosun Pharmaceutical : Axicabtagene Ciloleucel - Fosun Kite's CAR-T Cell Therapy Approved to be Included in the 2022 Version of Shanghai “Huhuibao”	PU
20/05/22	Shanghai Fosun Pharmaceutical : Fosun Pharma and VerImmune enter into an Exclusive License and Option Agreement for VerImmune’s Virus-inspired Particle (ViP) platform as Novel Immunotherapies in China	PU
28/04/22	Shanghai Fosun Pharmaceutical : NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS (H SHARES)	PU
28/04/22	Shanghai Fosun Pharmaceutical : FORM OF PROXY FOR HOLDERS OF H SHARES FOR THE 2022 FIRST MEETING OF HOLDERS OF H SHARES TO BE HELD ON WEDNESDAY, 1 JUNE 2022 (H SHARES)	PU
28/04/22	Shanghai Fosun Pharmaceutical : FORM OF PROXY FOR HOLDERS OF H SHARES FOR THE ANNUAL GENERAL MEETING TO BE HELD ON WEDNESDAY, 1 JUNE 2022 (H SHARES)	PU